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Abstract: Cancer metastasis is a complex processes, associated with the invasion to tissues with extensive degradation of 
the surrounding normal components, penetration into vessels, circulation, and then invasion to normal tissues in body. It 
would be not surprising that tumor cells usurp pathways critical to the developing embryo during metastasis. For the better 
understanding of tumor metastasis, this review will highlight the recent progress and significance of the signal transduc-
tion pathways, relevant to developmental biology.  
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INTRODUCTION 
  Cancer deaths result from the local invasion and distant 
metastasis of tumor cells in ~90% of cases [1]. Cancer me-
tastasis is a complex series of processes, fundamentally as-
sociated with the invasion, which is the direct migration and 
penetration by cancer cells into neighboring tissues. Cancer 
cells leave the original tumor site, migrate and invade to tis-
sues with extensive degradation of the surrounding normal 
components such as extracellular matrix, penetrate into lym-
phatic and blood vessels, circulate through the bloodstream, 
and then invade normal tissues elsewhere in the body. Dur-
ing the process of primary and metastasized sites, one of 
critical events required is the growth of a new network of 
blood vessels, i.e., angiogenesis [2]. For our better under-
standing of their roles in regulating tumor metastasis, this 
review will highlight the significance of signal transduction 
pathways in developmental biology. It would be not surpris-
ing that tumor cells usurp pathways critical to the developing 
embryo, as many of the normal developmental programs 
include processes that are also seen during tumor metastasis, 
including epithelial to mesenchymal transition (EMT), tissue 
specific morphogenesis, cellular motility and invasion [3]. 
DEVELOPMENTAL SIGNAL PATHWAY IN CAN-
CER 
  The observation reinforces that the aggressive tumor cells 
that metastasize from the primary sites often usurp pathways 
that function during normal development [3]. Recent studies 
indicate that embryonic pathways have been shown to affect 
the survival of tumor initiating or stem cells and to orches-
trate a complex microenvironment, i.e., niche, that promotes 
tumor survival and progression [3]. Increased motility and 
invasiveness of certain cancer cells is associated with the 
process, the epithelial-to-mesenchymal transition (EMT),   
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which occurs during embryonic development [4]. EMT is an 
important change in cell phenotype, which allows the escape 
of epithelial cells from the structural constraints imposed by 
tissue architecture [5]. Although the observations of mor-
phology of various tumors indicated epithelial and mesen-
chymal components of tumors as metaplasia [6, 7], the EMT 
phenomenon was recognized by Elizabeth Hay in the early to 
mid1980’s to be a central process in early embryonic mor- 
phogenesis [4] and the phrase of epithelial to mesenchymal 
transition was appear in 1980’s with reference to the study of 
a cellular change elicited by extracellular matrix [8], and this 
phenomenon was further characterized by Hay [4].  
  Recent studies indicate that this transition phenomenon is 
the result of a complex physiologic process that includes 
dissolution of adherens junctions, loss of cell polarity, a 
change to spindle-like cell morphology, increased cell motil-
ity, loss of epithelial markers, and induction of mesenchymal 
markers [9-11]. The expression of vimentin is increased and 
E-cadherin mediated cell adhesion is perturbed in this proc-
ess [10, 12]. Over the last decade, evidence has mounted for 
cancer genetics, that they are fundamentally diseases, which 
associate genetic and epigenetic alterations, requiring the 
accumulation of genomic alterations that inactivate tumor 
suppressors and activate proto-oncogenes [13, 14]. The ac-
cumulation occurs in a stepwise manner, which progress 
from very early stage with a few or several alterations in 
human genome to advanced stages with numerous alterations 
leading to aggressive characteristics. Classical tumor sup-
pressors such as retinoblastoma 1 and p53 and oncogenes 
such as RAS and MYC have been extensively studied [15, 
16]. But recent studies also implicate numerous alterations, 
such as alterations of non-protein-coding RNAs expression 
and DNA damage checkpoint responses, are associated with 
structural aberrations of tumor suppressor and oncogene loci 
[17]. Those are involved in complicated and overlapping 
pathways that regulate the biologically important processes 
including cell-cycle progression, gene expression, DNA 
damage response and apoptosis [18]. 26    Current Genomics, 2008, Vol. 9, No. 1  Ishii and Saito 
  The multi-step model of tumor progression emphasizes 
the accumulation of genetic alterations as the central mecha-
nism driving tumorigenesis [13, 14]. In this view, it is indi-
cated that the normal cell is an almost passive recipient of 
the mutations, and its cancer-associated phenotypes are gov-
erned largely by somatic mutations during the course of tu-
mor progression [19, 20]. While the role of somatic muta-
tions has been extensively documented in determining tumor 
phenotype and many of the observed differences have been 
explained among different tumors [20], the biological regula-
tion of carcinogenesis and development of tumors in the mi-
croenvironment has been extensively studied in developmen-
tal biology and our emerging understanding of their roles in 
regulating tumor metastasis in the view of critical signal 
transduction pathways: notch, bone morphogenic protein 
(Bmp) and sonic hedgehog (Shh). 
EACH SIGNAL TRANSDUCTION  
1. Notch 
  Notch signaling is critical for cell-cell communication 
and regulates a broad spectrum of cell fate decisions during 
embryonic development and in the adult organism via stem 
cell proliferation, differentiation and cell death [21]. Notch is 
instrumental in regulating processes such as neurogenesis, 
somitogenesis and angiogenesis [22]. Notch proteins are 
members of the conserved transmembrane receptor family 
including four members, Notch 1 to 4 [21]. The Notch genes 
encode transmembrane receptors, which contain a large ex-
tra-cellular domain, composed of a variable number of epi-
dermal growth factor (EGF)-like repeats and an intracellular 
signaling domain, which consists of six ankyrin/cdc10 motifs 
and nuclear localization signals [23]. Notch receptors inter-
act through their extracellular domain with other membrane-
associated ligands, the Delta and Serrate/ Jagged families, 
which are composed of five proteins, Jagged1 and 2 and 
Delta-like 1, 3 and 4 [23]. Notch signaling is activated by 
ligand-receptor interaction and triggers proteolytic cleavages 
by the -secretase complex, which releases the Notch intra-
cellular domain into the nucleus. Notch intracellular domain 
binds to the CBF1 DNA binding protein of the transcrip-
tional activator complex, the activation of which can lead to 
the expression of target genes, such as Hes family genes, 
involved in cell growth and differentiation.  
  A progenitor cell with induced levels of Delta by Notch 
signaling during neuronal differentiation becomes a neuron 
and sends inhibitory signals to other progenitor cells to 
maintain their undifferentiated status, which inhibits the ex-
pression of Delta [24]. But Notch signaling is shown also to 
promote angiogenesis and EMT [25]. Notch1 and Notch4, 
along with Delta4 and Jagged1 play a role in the develop-
ment of cardiac and vascular systems during embryonic de-
velopment through downstream effectors of Notch signaling 
and target genes such as RBPJk,  HRT1, and HRT2 [25]. 
Notch1 and Notch4 double deficient mice have apparently 
normal vasculogenesis, but they show impaired angiogenesis 
in the embryo proper and placenta [26]. The study of Notch1 
mutants have a collapsed endocardium and show an absence 
of mesenchymal cells in the cardiac cushions, indicating that 
Notch has a significant role during cardiac development in 
the process of EMT [25]. Collectively, Notch is a critical 
mediator of both angiogenesis and EMT. 
  Alterations of the Notch signaling pathway have been 
implicated in cancer [3]. Recent studies indicate significant 
involvement of the Notch signaling pathway in initiation and 
development of breast cancer (reviewed in [27-29]). The 
oncogenic function of Notch1 and 4 is shown by studies of 
the mammary epithelial cell system [27-29]. Transgenic 
overexpression of the Notch intracellular domain of Notch1 
and Notch3 resulted in the development of mammary tumors 
[30]. However, demonstrating a linkage of cancer develop-
ment or metastasis with EMT, the potentially rapid and tran-
sient process in vivo has proven difficult and data connecting 
the relevance of this process to tumor progression is still 
somewhat limited and controversial. Indeed Notch signaling 
has been classified as either oncogenic or tumor-suppressive 
depending on the cell type, specific type of mutation within 
the Notch pathway, the timing in the context of transforma-
tion and metastasis and the tissue context [3, 31].  
  Stephen Paget’s 1889 proposal [32] that metastasis de-
pends on cross-talk between selected cancer cells (the 
‘seeds’) and specific organ microenvironments (the ‘soil’) 
still holds forth today [33], indicating the notion that the po-
tential of a tumor cell to metastasize depends on its interac-
tions with the homeostatic factors that promote tumor cell 
growth, survival, angiogenesis, invasion and metastasis [33]. 
A regulatory mechanism enabling certain tumor stem cells 
from a primary site to survive in further spreading is depend-
ing on the tissue of origin and the route of spread of metasta-
sis, and is highly consistent with the seed and soil hypothesis 
[3, 33]. Considering Notch signaling is regulated by timing 
and signal strength, the number of ligand-receptor system 
expressed on a tumor stem cell will directly affect niche in-
teractions, and the biological effect is codependent on main-
tenance of survival and avoidance of induction of apoptosis 
in cancer-initiating cells with carrying deleterious damages, 
and suggests that targeted suppression of the survival signal-
ing pathway may give the rationale for sensitizing cancer-
initiating cells to novel therapeutic approach. 
2. Bmp 
  Bmps, members of the Tgf-ß family of signaling pro-
teins, are secreted ligands that signal via  autocrine and 
paracrine mechanisms to regulate cell proliferation and dif-
ferentiation [34, 35]. Bmp ligands bind to cell surface-
associated proteins called bone morphogenic receptors type I 
and type II [34, 35]. Bmp proteins have also been associated 
with EMT. In cardiac cushion development, Bmp2 has been 
associated with EMT [36]. Bmp2 was shown to enhance 
formation of the cardiac jelly, to pattern the atrioventricular 
myocardium and to induce endocardial EMT [36]. Bmp2 is 
required for myocardial expression of Has2, a crucial com-
ponent of the cardiac jelly matrix [36]. During EMT, Bmp2 
promotes expression of the basic helix-loop-helix factor 
Twist1, implicated in EMT in cancer metastases, and the 
homeobox genes Msx1 and Msx2, indicating that Bmp2 has 
a crucial role in coordinating multiple aspects of AV canal 
morphogenesis [36]. On the other hand, Bmp4 has been 
shown to induce EMT in human ovarian cancer cells [37]. 
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epithelial ovarian cancer cells, it was shown that treatment 
with Bmp4 increased cellular adhesion, motility and invasion 
with up-regulation of EMT markers Snail and Slug and with 
down-regulation of E-cadherin, which are closely relevant to 
changes in the level of activated Rho GTPases [37]. A link 
between autocrine Bmp signaling mediated through the Rho 
GTPase family and Snail- and Slug-induced EMT is pro-
posed and suggested that it may collectively contribute to 
aggressive ovarian cancer behavior [37]. Bmp7, however, 
has been shown to antagonize Tgf-induced EMT [38-41], in 
the representative study of renal cells and in renal cell injury 
by systemic administration of recombinant human Bmp7, 
which led to repair of severely damaged renal tubular epithe-
lial cells, in association with reversal of chronic renal injury 
by counteracting to Tgf-1-induced EMT and reverses chro- 
nic renal injury, indicating evidence of cross talk between 
Bmp7 and Tgf-1 in the regulation of EMT [41]. As indi-
cated in organogenesis,mesenchymalcells may possess 
remarkable plasticity and can regain a fully differentiated 
epithelial phenotype via a mesenchymal-to-epithelial transi-
tion (MET) [38-40], Bmp7 is known to induce MET in nor-
mal and nontransformed cells [42, 43]. A cross-talk between 
Bmp7 and Tgf- signaling in the regulation of EMT in breast 
cancer is proposed, and Bmp7 was identified as a potential 
key molecule in therapy for metastatic bone disease [11]. 
3. SHH 
  The hedgehog family of signaling proteins, hedgehog 
ligands, Sonic (Shh), Indian (Ihh), and Desert (Dhh), are se-
creted proteins, which signal through autocrine and paracrine 
mechanisms to control cell proliferation, differentiation, and 
morphology [44]. The hedgehog proteins exert their function 
by binding to a 12-pass transmembrane protein called 
Patched (Ptch) [45], which relieves the inhibitory affect of 
Ptch on a serpentine protein called Smoothened (Smo), lead-
ing to hyper-phosphorylation of SMO [46, 47]. The signal 
pathway induces the activation and repression of target genes 
through the Gli family of transcription factors, Gli-1, -2, -3, 
which regulate the transcription of target genes.  
  SHH is shown to affect EMT [4, 48]. Disruption of Shh 
signaling by the inhibitor cyclopamine inhibited EMT in 
pancreatic cancer cell lines [48]. In the study, Shh inhibition 
with cyclopamine resulted in down-regulation of snail and 
up-regulation of E-cadherin, consistent with inhibition of 
EMT, and was mirrored by a striking reduction of in vitro 
invasive capacity, indicating that blockade of Shh signaling 
inhibits pancreatic cancer invasion and metastases [48]. It is 
suggested that by targeting specific cellular subpopulations, 
such as cancer-initiating cells or cancer stem cells likely in-
volved in tumor initiation at metastatic sites, Hh family in-
hibitors may provide a new paradigm for therapy of dissemi-
nated malignancies [48]. The stem cell targeting may be 
moiré realistic, particularly when used in combination with 
conventional anti-metabolites, which can reduce "bulk" tumor 
size, and eliminate so-called metastatic cancer stem cells [48]. 
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